CoChat

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer

Open access

Abstract

BACKGROUND: The KRAS gene is mutated in about 40 % of colorectal cancer (CRC) cases, which has been clinically validated as a predictive mutational marker of intrinsic resistance to anti-EGFR inhibitor (EGFRi) therapy. Since nearly 60 % of patients with a wild type KRAS fail to respond to EGFRi combination therapies, there is a need to develop more reliable molecular signatures to better predict response. Here we address the challenge of adapting a gene expression signature predictive of RAS pathway activation, created using fresh frozen (FF) tissues, for use with more widely available formalin fixed paraffin-embedded (FFPE) tissues. METHODS: In this study, we evaluated the translation of an 18-gene RAS pathway signature score from FF to FFPE in 54 CRC cases, using a head-to-head comparison of five technology platforms. FFPE-based technologies included the Affymetrix GeneChip (Affy), NanoString nCounter™ (NanoS), Illumina whole genome RNASeq (RNA-Acc), Illumina targeted RNASeq (t-RNA), and Illumina stranded Total RNA-rRNA-depletion (rRNA). RESULTS: Using Affy_FF as the "gold" standard, initial analysis of the 18-gene RAS scores on all 54 samples shows varying pairwise Spearman correlations, with (1) Affy_FFPE (r = 0.233, p = 0.090); (2) NanoS_FFPE (r = 0.608, p < 0.0001); (3) RNA-Acc_FFPE (r = 0.175, p = 0.21); (4) t-RNA_FFPE (r = -0.237, p = 0.085); (5) and t-RNA (r = -0.012, p = 0.93). These results suggest that only NanoString has successful FF to FFPE translation. The subsequent removal of identified "problematic" samples (n = 15) and genes (n = 2) further improves the correlations of Affy_FF with three of the five technologies: Affy_FFPE (r = 0.672, p < 0.0001); NanoS_FFPE (r = 0.738, p < 0.0001); and RNA-Acc_FFPE (r = 0.483, p = 0.002). CONCLUSIONS: Of the five technology platforms tested, NanoString technology provides a more faithful translation of the RAS pathway gene expression signature from FF to FFPE than the Affymetrix GeneChip and multiple RNASeq technologies. Moreover, NanoString was the most forgiving technology in the analysis of samples with presumably poor RNA quality. Using this approach, the RAS signature score may now be reasonably applied to FFPE clinical samples.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12920-016-0225-2

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow-chart of the procedure followed in the pre-processing and analysis of the data. Six datasets (1 FF and 5 FFPE, each with 54 samples and 18 genes) underwent quality control procedures before analysis. Thirty-nine [39] “good” samples and 16 “good” genes were retained. Correlation analyses were performed using mean scores from the sample pairs. The predictive ability of the 16–gene set was validated using the Affymetrix FF, Affymetrix FFPE and NanoString gene expression data, by the PAM method
Fig. 1 Flow-chart of the procedure followed in the pre-processing and analysis of the data. Six datasets (1 FF and 5 FFPE, each with 54 samples and 18 genes) underwent quality control procedures before analysis. Thirty-nine [39] “good” samples and 16 “good” genes were retained. Correlation analyses were performed using mean scores from the sample pairs. The predictive ability of the 16–gene set was validated using the Affymetrix FF, Affymetrix FFPE and NanoString gene expression data, by the PAM methodCC BY · PubMed Central
Fig. 2 Scatterplot of the second vs. first principal component (PC2 vs PC1) for the 54 Affymetrix FFPE samples. The 15 “bad” samples (with low PC1 scores) are colored red and were excluded from subsequent analyses. Each sample was labeled using the last 3 digits of its name (barcode)
Fig. 2 Scatterplot of the second vs. first principal component (PC2 vs PC1) for the 54 Affymetrix FFPE samples. The 15 “bad” samples (with low PC1 scores) are colored red and were excluded from subsequent analyses. Each sample was labeled using the last 3 digits of its name (barcode)CC BY · PubMed Central
Fig. 3 Scatterplots of the Affymetrix FF vs. Affymetrix FFPE (a) and NanoString FFPE (b) mean scores for the 54 samples. The red circles represent the 15 samples with “poor” RNA quality
Fig. 3 Scatterplots of the Affymetrix FF vs. Affymetrix FFPE (a) and NanoString FFPE (b) mean scores for the 54 samples. The red circles represent the 15 samples with “poor” RNA qualityCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 25

Metadata

Authors
Omolo, B., Yang, M., Lo, F. Y., Schell, M. J., Austin, S., Howard, K., Madan, A., & Yeatman, T. J.
Affiliations
  • University of South Carolina Upstate (US)
  • Covance (United States) (US)
  • Moffitt Cancer Center (US)
Corresponding author
Yeatman, Timothy J.
Venue
BMC Medical Genomics
Published
2016-10-19
Volume
9
Issue
1
Pages
65-65
ISSN
1755-8794 (ISSN-L)
OpenAlex
W2536826816
Cited by
25
References
44
Citations by year
2024: 1 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 9 · 2018: 2 · 2017: 2
FWCI
2.34
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Medical Genomics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • SU+ Digital Repository (Strathmore University) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Cancer Institute (U01CA157960)
  • The Burroughs Wellcome Fund (1015192)
  • Simons Foundation (282714)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
colorectal cancer, KRAS mutation, formalin-fixed paraffin-embedded tissue, fresh frozen tissue, EGFR inhibitor resistance, predictive biomarkers, NanoString nCounter, Affymetrix GeneChip, RNA sequencing, targeted RNA sequencing, platform comparison
MeSH terms
Formaldehyde, Humans, Mutation, Colorectal Neoplasms, Signal Transduction, Paraffin Embedding, Tissue Fixation, ras Proteins, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer. https://app.cochat.ai/papers/10.1186/s12920-016-0225-2
The paper
Omolo, B., Yang, M., Lo, F. Y., Schell, M. J., Austin, S., Howard, K., Madan, A., & Yeatman, T. J. (2016). Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer. BMC Medical Genomics. https://doi.org/10.1186/s12920-016-0225-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.